BPI-361175

· Xcovery Holdings, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BPI-361175, covering 2022-04-15 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]